Department of Biochemistry, College of Medicine, Catholic University of Korea, Seoul 137-701, Korea.
Int J Mol Sci. 2013 Aug 20;14(8):17204-20. doi: 10.3390/ijms140817204.
Acquisition of drug resistance leads to failure of anti-cancer treatments and therapies. Although several successive chemotherapies are available, along with efforts towards clinical applications of new anti-cancer drugs, it is generally realized that there is a long way to go to treat cancers. Resistance to anti-cancer drugs results from various factors, including genetic as well as epigenetic differences in tumors. Determining the molecular and cellular mechanisms responsible for the acquisition of drug resistance may be a helpful approach for the development of new therapeutic strategies to overcome treatment failure. Several studies have shown that the acquisition of drug resistance is tightly regulated by post-transcriptional regulators such as RNA binding proteins (RBPs) and microRNAs (miRNAs), which change the stability and translation of mRNAs encoding factors involved in cell survival, proliferation, epithelial-mesenchymal transition, and drug metabolism. Here, we review our current understanding of ribonucleoprotein complexes, including RBPs and miRNAs, which play critical roles in the acquisition of drug resistance and have potential clinical implications for cancer.
耐药性的获得导致抗癌治疗和疗法的失败。尽管有几种连续的化疗药物以及新抗癌药物的临床应用的努力，但人们普遍认识到，要治疗癌症还有很长的路要走。抗癌药物的耐药性是由多种因素引起的，包括肿瘤中的遗传和表观遗传差异。确定导致耐药性获得的分子和细胞机制可能有助于开发新的治疗策略来克服治疗失败。几项研究表明，药物耐药性的获得受到 RNA 结合蛋白 (RBPs) 和 microRNAs (miRNAs) 等转录后调节剂的严格调控，这些调节剂改变了参与细胞存活、增殖、上皮-间充质转化和药物代谢的编码因子的 mRNA 的稳定性和翻译。在这里，我们回顾了我们对核糖核蛋白复合物的理解，包括 RBP 和 miRNA，它们在耐药性的获得中发挥着关键作用，并对癌症具有潜在的临床意义。
